This is a StreetInsider.com Premium Only Page

Clovis Oncology (CLVS) – StreetInsider.com Reports

Dec 28, 2022 04:11 PM NASDAQ Announces Delisting of Securities of Tuscan Holdings Corp. II; Clovis Oncology, Inc.; ZyVersa Therapeutics, Inc.; Otonomy, Inc., and Forward Pharma A/S

Dec 12, 2022 07:22 AM Clovis Oncology (CLVS) Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286

Nov 16, 2022 04:37 PM Clovis Oncology (CLVS) says FDA requested it to voluntarily revise label to limit the indication of Rubraca

Nov 9, 2022 04:41 PM U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.95%

Nov 9, 2022 04:35 PM U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.95%

Nov 9, 2022 04:03 PM UPDATE: JPMorgan Downgrades Clovis Oncology (CLVS) to Underweight, 'Going-Concern Risk with Runway Ending in January'

Nov 9, 2022 08:32 AM UPDATE: Clovis Oncology (CLVS) Files Form 10-Q, Includes Update on Going Concern

Nov 9, 2022 08:21 AM Clovis Oncology (CLVS) to Resume Trading at 8:45 a.m.

Nov 9, 2022 07:55 AM Clovis Oncology (CLVS) Halted, News Pending

Oct 27, 2022 05:05 PM Clovis Oncology (CLVS) Presents Data from TRITON3 Phase 3 Trial of Rubraca

Oct 17, 2022 05:26 AM Clovis Oncology (CLVS) Reports Updated LuMIERE Phase 1 FAP-2286 Data

Oct 3, 2022 07:03 AM Clovis Oncology (CLVS) Announces TRITON3 Phase 3 Trial of Rubraca Achieves Primary Endpoint in Men with Metastatic Castration-Resistant Prostate Cancer with BRCA or ATM Mutations

Sep 21, 2022 08:01 AM Clovis Oncology (CLVS) and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Sep 13, 2022 08:01 AM Clovis Oncology (CLVS) Submits Applications for Rubraca Label Expansion in the US and European Union as First-line Maintenance Treatment in Women with Advanced Ovarian Cancer

Sep 12, 2022 05:38 AM Clovis Oncology (CLVS) Reports Strong Phase 3 ATHENA Data for Rubraca

Aug 8, 2022 08:05 AM Clovis Oncology (CLVS) Misses Q2 EPS by 9c

Aug 1, 2022 04:41 PM JPMorgan Assumes Clovis Oncology (CLVS) at Neutral

Jul 8, 2022 09:57 AM Clovis Oncology (CLVS) Climbs 22%

Jul 5, 2022 09:42 AM Increasing unusual put option volume: TTE MOMO CLVS

Jul 1, 2022 11:02 AM Clovis Oncology (CLVS) Climbs 30%

Jun 22, 2022 04:55 AM Increasing unusual option volume: CLAR UNIT BBD FSK CLVS ASHR

Jun 22, 2022 04:42 AM Stocks with Implied Volatility Movement

Jun 21, 2022 12:35 PM Clovis Oncology (CLVS) Near High end of Today's Range, Up 80%

Jun 14, 2022 02:02 PM Clovis Oncology (CLVS) Highlights Phase 1 Data from Ongoing Clinical Studies of Targeted Radiotherapy Candidate FAP-2286 at SNMMI Annual Meeting

Jun 14, 2022 09:55 AM Increasing unusual option volume: TTI ING AQB INDA HUSA CLVS

Jun 13, 2022 04:45 PM Clovis Oncology (CLVS) Climbs 38%

Jun 6, 2022 08:08 AM Clovis Oncology's (CLVS) Rubraca as First-Line Maintenance Treatment Significantly Improves PFS in Women with Advanced Ovarian Cancer in Primary Efficacy Analyses Regardless of BRCA Mutation and HRD S

Jun 6, 2022 04:05 AM Stocks with Implied Volatility Movement

Jun 3, 2022 03:16 AM Stocks with Implied Volatility Movement

May 4, 2022 08:06 AM Clovis Oncology (CLVS) Provides Update on Clinical Development Programs

May 4, 2022 08:05 AM Clovis Oncology (CLVS) Misses Q1 EPS by 1c

Apr 5, 2022 03:05 AM Increasing unusual put option volume: CLVS ATER UMC FLR APRN TWTR

Apr 1, 2022 03:59 AM Increasing unusual put option volume: CLVS MGNI AKBA PATH

Mar 31, 2022 09:41 AM Increasing unusual call option volume: MULN CLVS SMSI ISPO CLVR

Mar 31, 2022 09:11 AM Pre-Open Stock Movers 03/31: (CLVS) (IZEA) (VIPS) Higher; (AMLX) (PATH) (EXFY) Lower (more...)

Mar 31, 2022 06:15 AM Clovis Oncology (CLVS) Climbs 39% After Rubraca Significantly Improves PFS in First-line Maintenance Treatment in Women with Ovarian Cancer

Mar 31, 2022 06:03 AM Clovis Oncology (CLVS) Reports Rubraca Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3

Feb 25, 2022 08:09 AM Clovis Oncology (CLVS) Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidat

Feb 24, 2022 06:12 AM Clovis Oncology (CLVS) PT Lowered to $5 at H.C. Wainwright

Feb 23, 2022 08:09 AM Clovis Oncology (CLVS) Tops Q4 EPS by 6c

Feb 16, 2022 07:23 AM Clovis Oncology (CLVS) PT Lowered to $1.50 at Goldman Sachs

Jan 26, 2022 09:02 AM Clovis Oncology (CLVS) PT Lowered to $3 at BofA Securities

Jan 10, 2022 08:00 AM Clovis Oncology (CLVS) Reports Prelim Q4 Results

Dec 9, 2021 08:06 AM Clovis Oncology (CLVS) Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Nov 3, 2021 08:11 AM Clovis Oncology (CLVS) Misses Q3 EPS by 8c; Reports $171.9M in Cash and Cash Equivalents

Oct 19, 2021 08:04 AM Clovis Oncology (CLVS), ITM Announce Lutetium-177 Clinical Supply Agreement

Oct 7, 2021 09:04 AM Clovis Oncology (CLVS) Announces Pan-Cancer Analysis Suggests Fibroblast Activation Protein is Attractive Target for Peptide-Targeted Radionuclide Therapy with FAP-2286

Sep 20, 2021 08:00 AM Clovis Oncology (CLVS) Retires Remaining 2021 Notes and Raises Additional Capital through its ATM Equity Offering Program

Aug 24, 2021 05:56 AM Clovis Oncology (CLVS) Announces Availability of and Reimbursement for Rubraca® in Switzerland

Aug 16, 2021 04:21 PM Clovis Oncology (CLVS) Announces Renewal of $125M At-The-Market Equity Offering Program